Cardiac embolism accounts for an increasing proportion of ischemic strokes and might
multiply several-fold during the next decades. However, research points to several potential …

Interventions. Copies: This document is available on the World Wide Web sites of the
American College of Cardiology (www. cardiosource. org), the American Heart Association …

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent
thromboembolic events without substantially increasing bleeding. We explored the …

Objectives: The aim of this study was to provide a quantitative appraisal of the effects on
clinical outcomes of radial access for coronary interventions in patients with coronary artery …

Abstract Aims Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant
ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both …

1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …

Background Patients with stable coronary artery disease and diabetes with previous
percutaneous coronary intervention (PCI), particularly those with previous stenting, are at …

Advances in antithrombotic therapy, along with an early invasive strategy, have reduced the
incidence of recurrent ischemic events and death in patients with acute coronary syndromes …

Background Bleeding following percutaneous coronary intervention has important
prognostic implications. The Academic Research Consortium (ARC) recently proposed a list …

Antiplatelet drugs, such as aspirin, P2Y12 antagonists, and glycoprotein (GP) IIb/IIIa
inhibitors, have proved to be successful in reducing the morbidity and mortality associated …